OTSKF News and Press, Otsuka Holdings Co. Ltd. From 10/28/21

Aurinia Pharmaceuticals (NASDAQ:AUPH) rose 4.4% after speculation that several other pharma companies may be looking at the company. GlaxoSmithKline (NYSE:GSK), Roche (OTCQX:RHHBY) and Otsuka Pharmaceuticals (OTCPK:OTSKF)  are speculated are speculated to reviewing a poten...

Aurinia Pharmaceuticals (NASDAQ:AUPH) will report its Q2 2021 earnings after the closing bell today and investors will want to pay attention to sales and any color management provides on its lupus drug Lupkynis (voclosporin). Lupkynis just won FDA approval in January as the first oral th...

Akebia Therapeutics ([[AKBA]] +1.9%) announced that it submitted a New Drug Application (“NDA”) to the FDA seeking approval for Vadadustat for the treatment of anemia due to chronic kidney disease (“CKD”) in adults irrespective of their dialysis therapy.Within...

The following slide deck was published by Otsuka Holdings Co., Ltd. in conjunction with this event. For further details see: Otsuka Holdings (OTSKY) Investor Presentation - Slideshow

Otsuka Pharmaceutical (OTSKF) submitted a marketing application to the Pharmaceuticals and Medical Devices Agency in Japan, seeking approval for difamilast (OPA-15406), a phosphodiesterase 4 (PDE4) inhibitor in patients with atopic dermatitis.Otsuka entered into a licensing agr...

Otsuka Pharmaceutical Co., Ltd. ( OTCPK:OTSKF ) unit Astex Pharmaceuticals will collaborate with The University of Texas MD Anderson Cancer Center aimed at accelerating the clinical evaluation of Astex's pipeline of products for leukemia patients, including myelodysplastic syndromes (MDS...

Following up on its announcement of positive data in May, Akebia Therapeutics (NASDAQ: AKBA ) announces mixed final results from two open-label Phase 3 clinical trials, PRO 2 TECT-CONVERSION and  PRO 2 TECT-CORRECTION , evaluating vadadustat in adult chronic kidney disease p...

Quick Take Keros Therapeutics ( KROS ) intends to raise $75 million from the sale of its common stock, per an amended S-1/A regulatory filing . The company is advancing a pipeline of drug treatment candidates for hematological and musculoskeletal diseases. KROS is entering Phase 2 trial...

Quick Take Keros Therapeutics ( KROS ) has filed to raise $86.25 million in an IPO of its common stock, according to an S-1 registration statement . The firm is a clinical stage biopharma developing a pipeline of drug candidates for the treatment of hematological and musculoskeletal disor...

Teva Pharmaceutical Industries (NYSE: TEVA ) announces positive results from two Phase 2/3 clinical trials in Japan evaluating Ajovy (fremanezumab) in patients with chronic and episodic migraine. More news on: Teva Pharmaceutical Industries Limited, Otsuka Holdings Co., Ltd., Otsuka Hold...